BioNTech (NASDAQ:BNTX) Shares Up 4.4%

BioNTech SE (NASDAQ:BNTX) shares rose 4.4% during trading on Thursday . The stock traded as high as $273.88 and last traded at $271.00. Approximately 16,905 shares changed hands during trading, a decline of 99% from the average daily volume of 2,197,576 shares. The stock had previously closed at $259.61.

Several research firms have recently weighed in on BNTX. Berenberg Bank set a $130.00 price target on BioNTech and gave the stock a “buy” rating in a research note on Tuesday, April 6th. JPMorgan Chase & Co. set a $104.00 target price on shares of BioNTech and gave the company a “neutral” rating in a research note on Tuesday, April 6th. Wolfe Research initiated coverage on shares of BioNTech in a research note on Monday. They issued an “outperform” rating and a $248.00 price target for the company. SVB Leerink restated a “hold” rating on shares of BioNTech in a research report on Wednesday, June 23rd. Finally, Redburn Partners reaffirmed a “sell” rating and issued a $146.00 target price on shares of BioNTech in a research report on Wednesday, June 16th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. BioNTech presently has an average rating of “Hold” and a consensus target price of $169.83.

The firm has a market cap of $66.49 billion, a price-to-earnings ratio of 45.47 and a beta of -1.58. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.70 and a quick ratio of 2.58. The business has a 50 day moving average of $217.35.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Sunday, May 9th. The company reported $4.39 EPS for the quarter, topping the consensus estimate of $3.09 by $1.30. BioNTech had a net margin of 48.40% and a return on equity of 91.61%. The business had revenue of $2.05 billion for the quarter, compared to analysts’ expectations of $1.40 billion. The business’s revenue was up 7294.9% on a year-over-year basis. As a group, equities analysts anticipate that BioNTech SE will post 31.59 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Compagnie Lombard Odier SCmA lifted its position in BioNTech by 959.1% during the second quarter. Compagnie Lombard Odier SCmA now owns 24,465 shares of the company’s stock valued at $5,469,000 after purchasing an additional 22,155 shares during the last quarter. Schroder Investment Management Group raised its position in BioNTech by 8.0% during the first quarter. Schroder Investment Management Group now owns 62,213 shares of the company’s stock valued at $6,793,000 after purchasing an additional 4,606 shares during the period. Optiver Holding B.V. purchased a new position in shares of BioNTech in the 1st quarter worth approximately $18,630,000. TownSquare Capital LLC bought a new position in shares of BioNTech during the 1st quarter valued at approximately $269,000. Finally, Bamco Inc. NY raised its holdings in BioNTech by 73.3% during the 1st quarter. Bamco Inc. NY now owns 252,977 shares of the company’s stock valued at $27,623,000 after buying an additional 107,014 shares during the period. Hedge funds and other institutional investors own 12.42% of the company’s stock.

BioNTech Company Profile (NASDAQ:BNTX)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.

See Also: What is the float in trading stocks?

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.